On April 9, 2018 F-star, a biopharmaceutical company developing novel bispecific antibodies, reported that new preclinical data from its lead immuno-oncology programme FS118 will be highlighted at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in Chicago, US from 14 – 18 April 2018 (Press release, f-star, APR 9, 2018, View Source [SID1234526828]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
FS118 is a first-in-class bispecific antibody that simultaneously blocks LAG-3 (Lymphocyte -Activation Gene 3) and PD-L1 (Programmed Death-Ligand 1) two key pathways in tumours evading the immune system. The new preclinical data show evidence of FS118’s efficacy both in primary human T cell assays and syngeneic tumour models. Specifically, FS118 is able to suppress LAG-3 expression on T cells in the tumour microenvironment and to promote a potent CD8+ T cells-mediated anti-cancer immune
response.
Neil Brewis, CSO of F-star commented: "Despite major advances on the PD-1/PD-L1 axis, many patients remain unresponsive to or relapse following treatment. FS118 preclinical data suggest that it can improve both efficacy and response rate compared to monotherapies or monotherapy combinations. It is a very exciting time for F-star, as these studies support the potential for FS118 to provide significant clinical benefits to cancer patients."
The new data will be published in a poster entitled "Dual blockade of PD-L1 and LAG-3 with FS118, a unique bispecific antibody, induces CD8+ T cell activation and modulates the tumour microenvironment to promote anti-tumour immune responses".
Details are below:
Session Title: Immune Checkpoints 2
Session Start Time: Monday, 16th April at 1pm
Session End Time: Monday, 16th April at 5pm
Location: Poster Section 32
Poster Board Number: 11
Poster Number: 2719
In June 2017, Merck and F-star entered into a new strategic collaboration that provides Merck with an exclusive option to acquire several immuno-oncology bispecific assets, including FS118, through the acquisition of F-star Delta Ltd
For further information, please contact:
At F-star For media enquiries
Pierre Peotta
Communications Manager
+44 (0)7392 080 279
[email protected]
Instinctif Partners (EU & RoW)
Sue Charles/Ashley Tapp
+44 (0)20 7866 7923
[email protected]
Lazar Partners (USA)
Glenn Silver
+1 (0)212 867 1762
[email protected]